Skip to content
lifestyle.dietfitnessforall.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Invivyd, Inc.
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
October 14, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
September 29, 2026
Invivyd to Participate in Key Investor Conferences – Sept 2026
September 8, 2026